While the much-talked-about patent cliff won’t hit until 2011, 2010 will still see patent expirations of some of the industry’s blockbuster drugs. Teva, Apotex, Mylan and a slew of other generic drugmakers will have a chance to put a dent in the sales of a number of brand meds this year – including Flomax and Aricept.
What qualifications are most important for pharma sales reps? You can forget business know-how; you can even overlook personal charm. The most important thing a sales rep needs to have is experience, says a new survey conducted by the Hay Group.
Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences (PNAS), Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells. The research suggests a method for developing vaccines against a wide variety of cancers.
Continue reading ‘New Strategy Produces Promising Advance in Cancer Vaccines’
Now that it’s done a $39.3 billion deal for Alcon, Novartis is joining the “no-megamerger” pharma fraternity. At the company’s annual shareholders’ meeting in Basel, Switzerland, new CEO Joe Jiminez said Novartis might scout for acquisitions to grow its business in certain areas, but another big-time deal just isn’t in the cards.
Continue reading ‘Novartis Eyes Deals in Generics, Vaccines’
You are currently browsing the weblog archives for the Strategy category.
Biotech Trading Signals Pharma News Biotech News